Clinical studies have demonstrated that taking Semaglutide for a year can result in an average weight loss of 15% of a person’s body weight. This translates to a weight loss of about 24-36 pounds for the average patient. The study involved individuals with a BMI greater than 30 who took Semaglutide once a week for a year. The treatment group lost an average of 15% of their body weight, equivalent to 37 pounds for a person weighing 250 pounds.
Learn about how you can use semaglutide to manage your wight here.
Learn more about how semaglutide works here.
The conclusion of the STEP2 clinical trial for semaglutide was that semaglutide, a GLP-1 receptor agonist administered once weekly via subcutaneous injection, led to significant weight loss in overweight or obese adults with type 2 diabetes compared to placebo. Additionally, semaglutide treatment resulted in improvements in glycemic control and other cardiometabolic risk factors such as blood pressure and lipid levels. These findings suggest that semaglutide has the potential to be an effective treatment option for weight management in individuals with type 2 diabetes, offering both weight loss benefits and improvements in metabolic health.
The study published in the New England Journal of Medicine evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for weight management in adults with obesity or overweight. The trial included 1,961 participants who were randomized to receive either semaglutide subcutaneous injections or placebo for 68 weeks.
The results showed that participants treated with semaglutide experienced significantly greater weight loss compared to those receiving placebo. The mean weight loss with semaglutide was 14.9% of baseline body weight, whereas the placebo group had a mean weight loss of 2.4%. Additionally, a greater proportion of participants in the semaglutide group achieved weight loss of at least 5% and 10% of their baseline body weight compared to the placebo group.
Furthermore, semaglutide treatment was associated with improvements in cardiometabolic risk factors such as waist circumference, blood pressure, and lipid levels. Adverse events were reported more frequently in the semaglutide group, with gastrointestinal events being the most common.
Overall, the study concluded that semaglutide demonstrated significant efficacy in promoting weight loss and improving cardiometabolic health in adults with obesity or overweight. However, adverse events were more common with semaglutide treatment.